The estimated effects of fibrate therapy on plasma concentration and activity of PAI-1 were independent of treatment duration and changes in plasma triglyceride levels in the meta-regression analysis .
This meta- analysis of RCTs suggested that fibrate therapy does not reduce plasma concentration or activity of PAI-I. The putative benefits of fibrate therapy in patients with cardiovascular disease appear to be exerted via mechanisms independent of effects on PAI-1
OBJECTIVE The aim of this systematic review was to perform a meta- analysis of r and omized controlled trials ( RCTs ) examining the efficacy of fibrate therapy in reducing plasma concentration or activity of plasminogen activator inhibitor 1 ( PAI-1 ) .
Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis.
We investigated the effects of fenofibrate , peroxisome proliferator-activated receptors ( PPARs ) agonist , on endothelial function in patients with hypertriglyceridemia . We administered placebo or fenofibrate 200 mg daily to 25 patients with hypertriglyceridemia for 8 weeks . This study was r and omized , double-blind , placebo-controlled , crossover in design . Compared with placebo , fenofibrate significantly changed lipoprotein levels including non-HDL cholesterol and significantly improved the percent flow-mediated dilator response to hyperemia by 13 + /- 6 % ( P < 0.001 ) and lowered plasma levels of tumor necrosis factor-alpha by 13 + /- 3 % ( P < 0.001 ) . Fenofibrate reduced fibrinogen and plasminogen activator inhibitor type 1 antigen levels by 17 + /- 3 and 10 + /- 3 % , respectively ( P < 0.001 and P = 0.014 , respectively ) . However , fenofibrate did not significantly change plasma levels of nitrate , malondialdehyde , tissue factor activity , and serological markers of plaque stabilization . Fenofibrate significantly changed lipoprotein levels and improved the percent flow-mediated dilator response to hyperemia as well as lowered levels of tumor necrosis factor-alpha ( TNF-alpha ) , fibrinogen , and plasminogen activator inhibitor type 1 antigen
The estimated effects of fibrate therapy on plasma concentration and activity of PAI-1 were independent of treatment duration and changes in plasma triglyceride levels in the meta-regression analysis .
This meta- analysis of RCTs suggested that fibrate therapy does not reduce plasma concentration or activity of PAI-I. The putative benefits of fibrate therapy in patients with cardiovascular disease appear to be exerted via mechanisms independent of effects on PAI-1
OBJECTIVE The aim of this systematic review was to perform a meta- analysis of r and omized controlled trials ( RCTs ) examining the efficacy of fibrate therapy in reducing plasma concentration or activity of plasminogen activator inhibitor 1 ( PAI-1 ) .